

USSN: 10/632,742


Ref. No. PC 27169

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


1. (Currently Amended) A compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein:

A is



X¹ and Y¹ together form the group -C(=O)N(R⁵)- wherein X¹ is NR⁵ and Y¹ is C(=O)

Z¹ is

- (a) NHC(=O)R¹, or
- (b) NHC(=S)R¹;
- (c) —NH—het¹;
- (d) —O—het¹;
- (e) —S—het¹, or
- (f) —het²;

R¹ is

- (a) NH₂,
- (b) NHC₁₋₄alkyl,
- (c) C₁₋₄alkyl,
- (d) C₂₋₄alkenyl,
- (e) -CH₂C(=O)C₁₋₄alkyl,
- (f) OC₁₋₄alkyl,

USSN: 10/632,742

Ref. No. PC 27169

(g) $\text{SC}_{1-4}\text{alkyl}$, or(h) $\text{C}_{3-6}\text{cycloalkyl}$;

Each X, Y, and Z is independently selected from

(a) H,

(b) Cl,


(c) F, or

(d) CH_3 R^4 is

(a) H,

(b) $\text{C}_{1-4}\text{alkyl}$,(c) $\text{OC}_{1-4}\text{alkyl}$,(d) $\text{SC}_{1-4}\text{alkyl}$, or(e) $\text{NHC}_{1-4}\text{alkyl}$; R^5 is

(a) H,

(b) $\text{C}_{1-4}\text{alkyl}$, or(c) $-(\text{CH}_2)_n-\text{W}_1-(\text{CH}_2)_n-\text{Z}^3$; W_1 is(a) $-\text{CH}_2-$,(b) $-\text{CH}=\text{CH}-$,(c) $-\text{C}\equiv\text{C}-$, or Z^3 is W_2 is(a) $-\text{O}-$,

USSN: 10/632,742

Ref. No. PC 27169

(b) $-N(R_{25})-$, or(c) $-C(=O)-N(R_{25})-$, wherein either the carbon or the nitrogen atom of the amide may be bound to a carbon atom of the phenyl ring of Z^3 ; R_{22} is $(CH_2)_tNR_{23}R_{24}$, H, halo, C_{1-4} alkyl, $-CN$, $-OH$, $-O-C_{1-4}$ alkyl, $-S(O)_uC_{1-4}$ alkyl, and $-C(=O)NH_2$ R_{23} is H or C_{1-4} alkyl; R_{24} is H, C_{1-4} alkyl, $-S(O)_2-C_{1-4}$ alkyl, $-C(=O)-C_{1-4}$ alkyl, $-C(=NH)-NH_2$, $-C(=O)-C(HR_{26})-NR_{27}R_{28}$; R_{25} is H or C_{1-4} alkyl; R_{26} is H, C_{1-4} alkyl which can be optionally substituted by $-OH$, $-NH_2$, $-NH-C(=NH)-NH_2$, $-SH$, $-SCH_3$, $-COOH$, $-C(O)NH_2$, and phenyl which can be optionally substituted with $-OH$, imidazole, indole, or R_{26} and R_{27} together with the carbon atom to which R_{26} attaches and the nitrogen atom to which R_{27} attaches form a heterocyclealkyl; R_{27} is H or C_{1-4} alkyl; R_{28} is H, C_{1-4} alkyl, $-S(O)_2-C_{1-4}$ alkyl, $-C(=O)-C_{1-4}$ alkyl, $-C(=NH)-NH_2$, $-C(=O)-C(HR_{26})-NR_{27}R_{27}$ t is 0, 1; u is 0, 1, 2; n is 1 or 2; and ~~het^1 is a C linked five (5) or six (6) membered heterocyclic ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen; het^1 being optionally substituted on one or more carbon atoms by 1-2 substituents selected from C_1-C_4 alkyl, amino, C_1-C_4 alkylamino, C_1-C_4 alkyloxy, halogen $-CN$, $=O$, $=S$, and being optionally substituted with C_1-C_4 alkyl;~~~~—— het^2 is a N linked five (5) or six (6) membered heterocyclic ring having at least one nitrogen atom, and optionally having one oxygen or sulfur atom; het^2 being optionally substituted on one or more carbon atoms by 1-2 substituents selected from C_1-C_4 alkyl, amino, C_1-C_4 alkylamino, C_1-C_4 alkyloxy, halogen $-CN$, $=O$, $=S$, and being optionally substituted with C_1-C_4 alkyl;~~~~—— heterocyclealkyl is a four (5) or seven (7) membered saturated heterocyclic ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and~~

USSN: 10/632,742

Ref. No. PC 27169

~~nitrogen; heterocycloalkyl being optionally substituted on one or more carbon atoms by 1-2 substituents selected from C₁-C₄alkyl, amino, C₁-C₄alkylamino, C₁-C₄alkyloxy, halogen-CN, =O, =S, and being optionally substituted with C₁-C₄alkyl;~~

at each occurrence, alkyl, alkenyl, or cycloalkyl is optionally substituted with 1-3 halo, -OH, -OC₁₋₄alkyl, and

~~Aryl refers to phenyl, biphenyl, or naphthyl, optionally substituted with halo, C₁₋₄alkyl, OH, OC₁₋₄alkyl, CH₂NH₂, CH₂NH(C₁₋₄alkyl), and S(O)_nC₁₋₄alkyl.~~

2. (Canceled)

3. (Original) The compound of claim 1, wherein X is F.

4. (Original) The compound of claim 3, wherein Y is F.

5. (Original) The compound of claim 1, wherein Z¹ is -NH-C(O)R₁.

6. (Original) The compound of claim 5, wherein R₁ is selected from C₁₋₄alkyl optionally substituted with 1-3 halo.

7. (Original) The compound of claim 6, wherein R₁ is C₁₋₄alkyl substituted with 1-2 halo.

8. (Original) The compound of claim 1, wherein Z¹ is -NH-C(S)R₁.

9. (Original) The compound of claim 8, wherein R₁ is selected from C₁₋₄alkyl optionally substituted with 1-3 halo.

10. (Original) The compound of claim 9, wherein R₁ is C₁₋₄alkyl substituted with 1-2 halo.

11. (Original) The compound of claim 1, wherein Y¹ is -C(=O)- and X¹ is -N(R₅)-.

USSN: 10/632,742

Ref. No. PC 27169

12. (Canceled)

13. (Original) A compound selected from the group consisting of

N-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

N-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;

2,2-dichloro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide;

2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

N-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

2,2-dichloro-*N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

N-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroethanethioamide;

N-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroacetamide;

N-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;

N-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)propanamide;

2,2-dichloro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;

2,2-difluoro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide;

USSN: 10/632,742

Ref. No. PC 27169

2,2-difluoro-N-(((5S)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)ethanethioamide;
(((5S)-3-[4-(1-methyl-6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;
N-(((5S)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;
N-(((5S)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanamide;
2,2-difluoro-N-(((5S)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)ethanethioamide;
N-(((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;
N-(((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanamide;
N-(((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)-2,2-difluoroethanethioamide;
N-(((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)acetamide;
2,2-difluoro-N-(((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)ethanethioamide;
N-(((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)propanamide; and
N-(((5S)-3-[4-(1-methyl-2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide.

14. (Original) A compound selected from the group consisting of

N-(((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide; N-(((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanamide;
N-(((5S)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;

USSN: 10/632,742

Ref. No. PC 27169

N-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)acetamide;

N-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)propanamide;

{{(5*S*)-3-[4-(1-methyl-6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl}acetamide;

N-({(5*S*)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;

N-({(5*S*)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanamide;

N-({(5*S*)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;

N-({(5*S*)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanamide;

N-({(5*S*)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)acetamide;

N-({(5*S*)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)propanamide; and

N-({(5*S*)-3-[4-(1-methyl-2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide.

15. (Original) A compound selected from the group consisting of

2,2-dichloro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;

2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)ethanethioamide;

2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;

2,2-dichloro-*N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;

USSN: 10/632,742

Ref. No. PC 27169

N-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)-2,2-difluoroethanethioamide;
N-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)-2,2-difluoroacetamide;
2,2-dichloro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)acetamide;
2,2-difluoro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)ethanethioamide;
2,2-difluoro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)ethanethioamide;
2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)ethanethioamide;
N-({(5*S*)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)-2,2-difluoroethanethioamide; and
2,2-difluoro-*N*-({(5*S*)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)ethanethioamide.

16. (Canceled)

17. (Original) A method for the treatment of microbial infections in mammals comprising administration of an effective amount of compound of claim 1 to said mammal.

18. (Original) The method of claim 17 wherein said compound of claim 1 is administered to the mammal orally, parenterally, transdermally, or topically in a pharmaceutical composition.

19. (Original) The method of claim 18 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

USSN: 10/632,742

Ref. No. PC 27169

20. (Original) The method of claim 18 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.

21. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.